BACKGROUND: Data on human papillomavirus (HPV) prevalence are essential for developing cost-effective cervical cancer prevention programs. METHODS: In 2005, 710 human immunodeficiency virus (HIV)-positive and 226 HIV-negative Rwandan women enrolled in an observational prospective cohort study. Sociodemographic data, CD4+ cell counts, and cervical specimens were obtained. Cervicovaginal lavage specimens were collected from each woman and tested for >40 HPV types by a polymerase chain reaction assay; HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 were considered primary carcinogenic HPV types. RESULTS: The prevalence of HPV was higher in HIV-positive women than in HIV-negative women in all age groups. Among HIV-infected women, 69% were positive for >or=1 HPV type, 46% for a carcinogenic HPV type, and 10% for HPV-16. HPV prevalence peaked at 75% in the HIV-positive women aged 25-34 years and then declined with age to 37.5% in those >or=55 years old (Ptrend<.001). A significant trend of higher prevalence of HPV and carcinogenic HPV with lower CD4+ cell counts and increasing cytologic severity was seen among HIV-positive women. CONCLUSIONS: We found a higher prevalence of HPV infection in HIV-positive than in HIV-negative Rwandan women, and the prevalence of HPV and carcinogenic HPV infection decreased with age.
BACKGROUND: Data on human papillomavirus (HPV) prevalence are essential for developing cost-effective cervical cancer prevention programs. METHODS: In 2005, 710 human immunodeficiency virus (HIV)-positive and 226 HIV-negative Rwandan women enrolled in an observational prospective cohort study. Sociodemographic data, CD4+ cell counts, and cervical specimens were obtained. Cervicovaginal lavage specimens were collected from each woman and tested for >40 HPV types by a polymerase chain reaction assay; HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 were considered primary carcinogenic HPV types. RESULTS: The prevalence of HPV was higher in HIV-positive women than in HIV-negative women in all age groups. Among HIV-infectedwomen, 69% were positive for >or=1 HPV type, 46% for a carcinogenic HPV type, and 10% for HPV-16. HPV prevalence peaked at 75% in the HIV-positive women aged 25-34 years and then declined with age to 37.5% in those >or=55 years old (Ptrend<.001). A significant trend of higher prevalence of HPV and carcinogenic HPV with lower CD4+ cell counts and increasing cytologic severity was seen among HIV-positive women. CONCLUSIONS: We found a higher prevalence of HPV infection in HIV-positive than in HIV-negative Rwandan women, and the prevalence of HPV and carcinogenic HPV infection decreased with age.
Authors: Patti E Gravitt; Anant M Kamath; Lynne Gaffikin; Z Michael Chirenje; Sharita Womack; Keerti V Shah Journal: Int J Cancer Date: 2002-08-20 Impact factor: 7.396
Authors: Nubia Muñoz; F Xavier Bosch; Silvia de Sanjosé; Rolando Herrero; Xavier Castellsagué; Keerti V Shah; Peter J F Snijders; Chris J L M Meijer Journal: N Engl J Med Date: 2003-02-06 Impact factor: 91.245
Authors: José E Levi; Bernhard Kleter; Wim G V Quint; Maria C S Fink; Cynthia L M Canto; Regina Matsubara; Iara Linhares; Aluísio Segurado; Bart Vanderborght; José Eluf Neto; Leen-Jan Van Doorn Journal: J Clin Microbiol Date: 2002-09 Impact factor: 5.948
Authors: Marc F D Baay; Eyrun F Kjetland; Patricia D Ndhlovu; Vanessa Deschoolmeester; Takafira Mduluza; Exenevia Gomo; Henrik Friis; Nicholas Midzi; Lovemore Gwanzura; Peter R Mason; Jan B Vermorken; Svein G Gundersen Journal: J Med Virol Date: 2004-07 Impact factor: 2.327
Authors: Thi Hoang Anh Pham; Trong Hieu Nguyen; Rolando Herrero; Salvatore Vaccarella; Jennifer S Smith; Thi Thuy Nguyen Thuy; Hoai Nga Nguyen; Ba Duc Nguyen; Rhoda Ashley; Peter J F Snijders; Chris J L M Meijer; Nubia Muñoz; D Max Parkin; Silvia Franceschi Journal: Int J Cancer Date: 2003-03-20 Impact factor: 7.396
Authors: R Newton; P J Ngilimana; A Grulich; V Beral; B Sindikubwabo; A Nganyira; D M Parkin Journal: Int J Cancer Date: 1996-03-28 Impact factor: 7.396
Authors: Philip E Castle; Ana C Rodriguez; Carolina Porras; Rolando Herrero; Mark Schiffman; Paula Gonzalez; Allan Hildesheim; Robert D Burk Journal: Sex Transm Dis Date: 2007-11 Impact factor: 2.830
Authors: Washington Mudini; Joel M Palefsky; Martin J Hale; Michael Z Chirenje; Rudo Makunike-Mutasa; Fiona Mutisi; Alltalents Murahwa; Altini Mario Journal: J Acquir Immune Defic Syndr Date: 2018-09-01 Impact factor: 3.731
Authors: R A Hanisch; P S Sow; M Toure; A Dem; B Dembele; P Toure; R L Winer; J P Hughes; G S Gottlieb; Q Feng; N B Kiviat; S E Hawes Journal: J Clin Virol Date: 2013-10-18 Impact factor: 3.168
Authors: Kathryn Anastos; Donald R Hoover; Robert D Burk; Antonio Cajigas; Qiuhu Shi; Diljeet K Singh; Mardge H Cohen; Eugene Mutimura; Charles Sturgis; William C Banzhaf; Philip E Castle Journal: PLoS One Date: 2010-10-20 Impact factor: 3.240
Authors: Georgette Adjorlolo-Johnson; Elizabeth R Unger; Edith Boni-Ouattara; Kadidiata Touré-Coulibaly; Chantal Maurice; Suzanne D Vernon; Marcel Sissoko; Alan E Greenberg; Stefan Z Wiktor; Terence L Chorba Journal: BMC Infect Dis Date: 2010-08-17 Impact factor: 3.090